Endocrinology

Top Story

Victoza will not be expanded for type 1 diabetes use

August 30, 2015

Novo Nordisk does not intend to submit an application to expand the label of Victoza for use in type 1 diabetes, following phase 3a trial results that showed a significantly higher rate of hypoglycemia in adults assigned the drug compared with those assigned a placebo.

"The results of the two ADJUNCT trials show that liraglutide as adjunct to insulin therapy met the primary endpoint of improving blood glucose control for people with type 1 diabetes, however, unfortunately without the hypoglycemic benefit experienced in type 2 diabetes,” Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said in a statement. "We are disappointed, as we believed in the potential to provide people with type 1 diabetes with a new treatment option, and we will continue to invest in new treatment options for this group of people."

In the Journals

Arsenic exposure linked to early puberty, obesity

August 29, 2015
Exposure to low levels of arsenic through drinking water in utero resulted in signs of early puberty and obesity as adults in female mice, according to recent findings…
In the Journals

Top 5 online obesity stories

August 28, 2015
Endocrine Today has compiled a list of the top five obesity stories posted in the last month.Healio.com/Endocrinology readers were interested in long-term follow-up of…
FDA News

FDA: DPP-IV inhibitors may cause severe joint pain

August 28, 2015
The FDA recently a warned that the medications Januvia, Onglyza, Tradjenta and Nesina may cause joint pain that is severe and disabling, according to a press release. It…
In the Journals

Growth hormone reduces osteoporotic fracture risk in older women

August 28, 2015
Older women with osteoporosis treated with growth hormone showed a reduced risk for fracture and improved bone density that continued for years after stopping treatment…
More News Headlines »
CME
Assessing Cornerstones for Successful Weight Loss

Assessing Cornerstones for Successful Weight Loss: Building a Foundation that Really Works

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc.

Obesity has increased dramatically in the past 2 decades and is now considered a health care epidemic in the United…
More »
Meeting News Coverage Video
VIDEO: Chef integrates food and medicine in promotion of cardiometabolic health

VIDEO: Chef integrates food and medicine in promotion of cardiometabolic health

August 10, 2015
NEW ORLEANS — Chef Leah Sarris, program director at the Goldring Center for Culinary Medicine at Tulane…
More »
CME
Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

Avoiding “Loss of Chance”…Improving the Screening, Treatment, and Referral of Patients with Diabetic Retinopathy

This activity is supported by an educational grant from Genentech, Inc.

Despite a number of effective treatment options, diabetic eye disease is a leading cause of vision loss in the United…
More »
Current Issues
View the Current Issues
morganatic-roan